GAUDIUMIVF

- Q1 FY27 Consolidated Revenue ₹19.4 Cr vs Q1 FY26 ₹17.8 Cr (▲9.1% YoY) - Q1 FY27 Consolidated EBITDA ₹2.4 Cr vs Q1 FY26 ₹5.2 Cr (▼52.96% YoY); EBITDA Margin 12.5% vs 29% (▼1650 bps) - Q1 FY27 Consolidated PAT ₹1.8 Cr vs Q1 FY26 ₹3.1 Cr (▼42.27% YoY) - Profit moderation is attributed to front-loaded expansion costs for the 27 hub rollout, including pre-operational spends, clinical talent hiring, and AI tool integration/marketing. - Excluding one-off expansion costs, adjusted EBITDA for Q1 FY27 would be approximately ₹5.35 Cr with an EBITDA margin of ~27.63%, in line with the steady-state operating profile. - Company expects to achieve 30% revenue growth for full FY27 and adjusted EBITDA margins similar to FY26 levels by year-end, citing Q1's lower growth due to seasonality. - The first IVF hub at South Extension, New Delhi, is operational; Gurgaon and Nagpur hubs are expected to be operational within 10 and 25 days respectively, contributing to the target of 10 new hubs in FY27. - Progressing on three international spokes in Paris, Nigeria, and Sydney; international patients currently contribute 25-30% of the patient mix. - First IVF chain in India to formally integrate AI-led embryology tools (SiD and ERICA), showing an approximate 8% improvement in first-attempt outcomes. - Board approved ₹15 Cr for Gaudium Women Hospital at Lucknow (commercialization FY28-FY29), to be funded by internal accruals. - Maintains a debt-light balance sheet with a consolidated debt-to-equity ratio of approximately 0.04 times.

- Audio recording of the Earnings Call on Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026, has been uploaded to the company's website on August 14, 2026.

- Gaudium IVF and Women Health Ltd. filed a Revised Investor Presentation for Q1 FY27 (quarter ended June 30, 2026). - Discloses a one-time marketing cost of Rs. 253.24 lakhs for SID and ERICA (both Standalone and Consolidated). - Corrected Adjusted EBITDA (Standalone): Rs. 507.75 lakhs (37.12% margin). - Corrected Adjusted EBITDA (Consolidated): Rs. 532.75 lakhs (27.49% margin). - This revised presentation supersedes the earlier filing dated August 13, 2026.

- Investor Presentation on the Financial Results for the quarter ended June 30, 2026 (Q1 FY27). - The presentation highlights a 62% success rate on first attempt and 85% on multiple attempts for IVF, with an average revenue per patient of Rs. 3.5 lakhs.

- Q1 FY27 Consolidated Revenue ₹19.4 Cr vs ₹17.8 Cr (▲9.13% YoY) - EBITDA ₹2.4 Cr vs ₹5.2 Cr (▼52.96% YoY) - PAT ₹1.8 Cr vs ₹3.1 Cr (▼42.27% YoY) - EBITDA Margin 12.51% vs 29.02% (▼1651 bps) - Company commenced operations at a new IVF Centre/Hub in South Extension, New Delhi. - Board approved the establishment of Gaudium Women Hospital, Lucknow, with an estimated project cost of up to ₹15 crore. - Profitability was consciously moderated due to investments ahead of expansion and pre-operationalisation costs for new hubs.

New Filing detected. See link for details.

- The Board of Directors approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. (Note: Consolidated results table is not provided in the filing, thus standalone figures are used below). - Q1 FY27 Standalone Operating Revenue ₹1,367.73 Lakhs vs ₹1,227.32 Lakhs (▲11.44% YoY) - EBITDA ₹329.76 Lakhs vs ₹415.55 Lakhs (▼20.64% YoY) - PAT ₹166.35 Lakhs vs ₹235.08 Lakhs (▼29.24% YoY) - EBITDA Margin 24.11% vs 33.86% (▼975bps) - Ram Rattan & Associates was re-appointed as Internal Auditor for FY 2026-27. - M/s. Suresh Nainwal & Company was appointed as Secretarial Auditor for 5 years (FY 2026-27 to FY 2030-31), subject to AGM approval. - The 11th Annual General Meeting (AGM) is scheduled for Monday, September 28, 2026.

- Q1 FY27 Consolidated Revenue from Operations ₹1,937.66 Lakhs vs ₹1,775.59 Lakhs (▲9.13% YoY) - EBITDA ₹354.77 Lakhs vs ₹515.28 Lakhs (▼31.15% YoY) - PAT ₹177.59 Lakhs vs ₹307.62 Lakhs (▼42.30% YoY) - EBITDA Margin 18.3% vs 29.0% (▼1070bps)

- Concall Schedule - Concall Date: August 14, 2026 - Concall Time: 02:00 P.M. IST

- Gaudium IVF unveiled AI Powered Signature Labs in South Delhi, marking the first milestone in a planned 19-centre expansion. - The new centre integrates AI-assisted embryology and globally benchmarked standards.

- Gaudium IVF and Women Health Limited commences commercial operations of a new IVF Centre/Hub in South Extension, New Delhi. - Operations are effective from July 16, 2026. - The Centre/Hub will provide In Vitro Fertilization (IVF) and Health Care Services, as per the IPO prospectus.

- Intimation for closure of trading window for designated persons and their relatives. - Effective from July 01, 2026, until 48 hours after the announcement of Q1 FY27 (June 30, 2026) financial results. - Board meeting date for results to be intimated separately.

- Corrigendum filed for inadvertent regrouping and typographical errors in the Consolidated Financial Results for the year ended March 31, 2025 (comparative figures). - The corrections are clerical and do not impact Profit After Tax, Net Worth, or the overall financial position for the current year ended March 31, 2026. - Minor adjustment to Profit After Tax for FY25 from ₹1,917.73 Lakhs to ₹1,917.86 Lakhs. - Standalone financial results for March 31, 2025, and March 31, 2026, were correctly reported and remain unchanged.

- Board approved setting up "Gaudium Women Hospital, Lucknow" in Uttar Pradesh. - The project involves a 30-year land lease with 10% net revenue share and a ₹3 crore security deposit. - Estimated project cost is up to ₹15 crore for development and operationalization.

- Concall Schedule - Concall Date: June 12, 2026 - Concall Time: 11:00 AM to 12:00 PM - Details: Virtual meeting with InsightX Conference, organized by Choice Broking. No unpublished price sensitive information will be shared.

Gaudium IVF and Women Health Limited has informed the exchanges about the availability of the audio recording of its Earnings Call. The call discussed the Audited Standalone and Consolidated Financial Results for the quarter and year ended March 31, 2026, and was held on May 29, 2026. The recording is accessible on the company's website.

Consolidated Revenue from Operations ₹30.35 Cr vs ₹26.92 Cr (▲12.74% YoY), EBITDA ₹12.17 Cr vs ₹8.72 Cr (▲39.56% YoY), PAT ₹8.36 Cr vs ₹6.45 Cr (▲29.46% YoY). EBITDA Margin 40.10% vs 32.39% (▲771 bps). The company also integrated AI-led embryology platforms in April 2026 and plans expansion into new IVF hubs.

Gaudium IVF and Women Health Limited reported strong Q4 FY26 consolidated results. Revenue from operations increased to ₹30.35 Cr from ₹26.92 Cr (▲12.73% YoY). EBITDA grew to ₹12.17 Cr from ₹8.72 Cr (▲39.56% YoY), and Net Profit (PAT) rose to ₹8.36 Cr from ₹6.46 Cr (▲29.45% YoY). EBITDA margin expanded significantly to 40.11% from 32.39% (▲772bps).

Gaudium IVF and Women Health Limited informed that the National Company Law Tribunal (NCLT), New Delhi Bench, vide its order dated May 15, 2026, rejected the petition filed by M/s. Ramaa Capital (Operational Creditor) against the company under the Insolvency and Bankruptcy Code, 2016. The company received the order on May 22, 2026, and stated that this outcome has no impact on its financial, operational, or other activities.

Gaudium IVF and Women Health Limited announced an Earnings Conference Call to discuss its Audited Standalone and Consolidated Financial Statements/Results for the quarter and year ended March 31, 2026. The call is scheduled for Friday, May 29, 2026, at 12:00 P.M. IST.